Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Berend Neuteboom

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Annals of Pharmacotherapy|October 6, 2005
Interferon beta-1a overdose in a multiple sclerosis patientNicola P Falcone, Agostino Nappo, Berend Neuteboom
Pharmaceutical Research|March 18, 2005
Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeysDonald E Mager, Berend Neuteboom, William J Jusko
The Journal of Pharmacology and Experimental Therapeutics|March 28, 2003
Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeysDonald E Mager, Berend Neuteboom, Constantinos Efthymiopoulos, et al.
Oncotarget|April 1, 2014
The immunocytokine NHS-IL12 as a potential cancer therapeuticJonathan Fallon, Robert Tighe, Giorgio Kradjian, et al.
Clinical Pharmacology and Therapeutics|September 26, 2019
Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial CarcinomaAna M Novakovic, Justin J Wilkins, Haiqing Dai, et al.
Mabs|December 20, 2014
A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast displayChristian Schröter, Ralf Günther, Laura Rhiel, et al.
International Journal of Cancer|February 10, 2009
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependencyTom Mikkelsen, Chaya Brodie, Susan Finniss, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 14, 2019
Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial CarcinomaJustin J Wilkins, Brigitte Brockhaus, Haiqing Dai, et al.
Oncoimmunology|September 6, 2021
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 bindingHulin Jin, Vittorio D'Urso, Berend Neuteboom, et al.
Protein Engineering, Design & Selection : PEDS|April 19, 2011
Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodiesMarco Muda, Alec W Gross, Jessica P Dawson, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Annals of Pharmacotherapy|October 6, 2005
Interferon beta-1a overdose in a multiple sclerosis patientNicola P Falcone, Agostino Nappo, Berend Neuteboom
Pharmaceutical Research|March 18, 2005
Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeysDonald E Mager, Berend Neuteboom, William J Jusko
The Journal of Pharmacology and Experimental Therapeutics|March 28, 2003
Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeysDonald E Mager, Berend Neuteboom, Constantinos Efthymiopoulos, et al.
Oncotarget|April 1, 2014
The immunocytokine NHS-IL12 as a potential cancer therapeuticJonathan Fallon, Robert Tighe, Giorgio Kradjian, et al.
Clinical Pharmacology and Therapeutics|September 26, 2019
Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial CarcinomaAna M Novakovic, Justin J Wilkins, Haiqing Dai, et al.
Mabs|December 20, 2014
A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast displayChristian Schröter, Ralf Günther, Laura Rhiel, et al.
International Journal of Cancer|February 10, 2009
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependencyTom Mikkelsen, Chaya Brodie, Susan Finniss, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 14, 2019
Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial CarcinomaJustin J Wilkins, Brigitte Brockhaus, Haiqing Dai, et al.
Oncoimmunology|September 6, 2021
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 bindingHulin Jin, Vittorio D'Urso, Berend Neuteboom, et al.
Protein Engineering, Design & Selection : PEDS|April 19, 2011
Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodiesMarco Muda, Alec W Gross, Jessica P Dawson, et al.
Pageof 2